Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TDP2 | O95551 | 2/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11247281 | 0.85 | SMN1; SMN2 (0.67) | AXLCYP1A2ALDH1A1CYP3A4CYP2A6 | |
| SCHEMBL2375581 | 0.80 | AXL (1.00) | AXLALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL5566954 | 0.78 | AXL (0.69) | AXLCYP1A2ALDH1A1CYP3A4MAPT | |
| SCHEMBL7264571 | 0.78 | SMN1; SMN2 (0.66) | AXLCYP1A2CYP3A4CYP11B1CYP11B2 | |
| SCHEMBL11846026 | 0.77 | AXL (0.92) | AXLALDH1A1MAPTSMN1; SMN2TDP2 | |
| SCHEMBL10952826 | 0.76 | CYP11B1 (0.45) | CYP1A2ALDH1A1CYP3A4CYP2A6CYP11B1 | |
| SCHEMBL11088597 | 0.73 | CYP11B1 (0.52) | CYP1A2ALDH1A1CYP3A4CYP2A6CYP11B1 | |
| SCHEMBL4734262 | 0.72 | AXL (0.51) | AXLCYP2A6CYP11B1CYP11B2KDM4E | |
| SCHEMBL27995075 | 0.72 | AXL (0.77) | AXLALDH1A1SMN1; SMN2TDP2PDE3B | |
| SCHEMBL4855241 | 0.70 | RAB9A (0.52) | ALDH1A1KDM4EMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11617738-B2 | 6-amino-2,4-dihydropyrano [2,3-c] pyrazoles and methods of use | PURDUE RESEARCH FOUNDATION (US) | 2023-04-04 | — | — | US | disclosed |
| US-20210196684-A1 | 6-AMINO-2,4-DIHYDROPYRANO [2,3-C] PYRAZOLES AND METHODS OF USE | PURDUE RESEARCH FOUNDATION (US) | 2021-07-01 | — | — | US | disclosed |
| US-10980781-B2 | 6-amino-2,4-dihydropyrano [2,3-c] pyrazoles and methods of use | PURDUE RESEARCH FOUNDATION (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200078336-A1 | 6-AMINO-2,4-DIHYDROPYRANO [2,3-C] PYRAZOLES AND METHODS OF USE | PURDUE RESEARCH FOUNDATION (US) | 2020-03-12 | — | — | US | disclosed |
| WO-2018183587-A1 | 6-AMINO-2,4-DIHYDROPYRANO [2,3-C] PYRAZOLES AND METHODS OF USE | PURDUE RESEARCH FOUNDATION (US) | 2018-10-04 | — | — | WO | disclosed |
| US-7262201-B1 | For the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals | ASTRAZENECA AB (SE) | 2007-08-28 | — | — | US | disclosed |
| EP-1119567-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-05-04 | — | — | EP | disclosed |
| EP-1119567-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000021955-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200078336-A1 | 6-AMINO-2,4-DIHYDROPYRANO [2,3-C] PYRAZOLES AND METHODS OF USE | USP7, USP3, USP2 | AXL 2748/4885CYP1A2 1484/4885ALDH1A1 647/4885 |
| US-20210196684-A1 | 6-AMINO-2,4-DIHYDROPYRANO [2,3-C] PYRAZOLES AND METHODS OF USE | USP7, USP3, USP2 | AXL 2748/4885CYP1A2 1484/4885ALDH1A1 647/4885 |
| US-10980781-B2 | 6-amino-2,4-dihydropyrano [2,3-c] pyrazoles and methods of use | USP7, USP3, USP2 | AXL 2748/4885CYP1A2 1484/4885ALDH1A1 647/4885 |
| US-11617738-B2 | 6-amino-2,4-dihydropyrano [2,3-c] pyrazoles and methods of use | USP7, USP3, USP2 | AXL 2748/4885CYP1A2 1484/4885ALDH1A1 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.